Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q3 EPS of ($0.65), $0.07 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $10.63 million versus the consensus estimate of $6.06 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.